Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Dose-escalation, Dose-finding, and Proof-of-concept Trial of SP-420 in Subjects With Transfusion-dependent β-thalassemia

Next Previous
Search
Trial Profile

An Open-label, Dose-escalation, Dose-finding, and Proof-of-concept Trial of SP-420 in Subjects With Transfusion-dependent β-thalassemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SP 420 (Primary)
  • Indications Beta-thalassaemia; Iron overload
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pharmacosmos

    • Most Recent Events

    • 05 Sep 2023 According to a Pharmacosmos media release, this week, first patient has been enrolled into this trial which is planned to include patients with transfusion-dependent beta-thalassemia from countries in North America, Europe, Middle East, Asia and Australia.
    • 05 Sep 2023 Status changed to recruiting, according to a Pharmacosmos media release.
    • 05 Sep 2023 According to a Pharmacosmos media release, following the Nov 2021 acquisition of AbFero Pharmaceuticals Inc including the drug candidate SP-420, Pharmacosmos A/S has initiated this Phase II trial in patients with transfusion-dependent beta-thalassemia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top